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Background
A voluminous literature attests to the robustness of con-
ventional EEG investigations and their clinical usefulness
in disorders of the brain function. With regards to the
pharmaco-EEG, general slowing of background activity,
an increase in paroxysmal theta or delta activity and the
development of epileptiform discharges are well docu-
mented with antipsychotic drugs. Although quetiapine
has been increasingly used as an antipsychotic there is
only limited knowledge about the potential risk of EEG
alterations including epileptiform activity and a lack of
systematic studies with this drug. We have retrospectively
analysed the EEG recordings of patients treated with the
new antipsychotic quetiapine and compared it with those
treated with olanzapine and haloperidol and a control
group of 30 healthy subjects.
Materials and methods
Digital EEG recordings of 81 patients were retrieved from
a database, based on the individual medication as main
selection criterion. Patients with organic brain disorders
or substance abuse were not eligible. All EEGs were
retrieved from the database and visually interpreted inde-
pendently by two experienced raters and one experienced
rater blind to medication, dosage and diagnosis of the
patients. Patient groups were defined by medication as
follows: quetiapine (n = 22), olanzapine (n = 37) or
haloperidol (n = 22). These groups were compared with
30 healthy subjects.
Results
Overall, there were no significant differences between the
four groups (three patient subgroups and one control
group) in sociodemographic parameters. Within the 4
subgroups results regarding abnormal EEG's differed sta-
tistically significantly. One patient from the quetiapine
group (5%), 13 olanzapine patients (35%), five of the
haloperidol patients (23%) and two subjects of the con-
trol group (7%) had an abnormal EEG. Epileptiform
activity was observed in four patients (11%) of the olan-
zapine group, and none in the others. EEG abnormalities
were statistically significantly increased with dose in the
olanzapine group, in contrast to patients treated with
haloperidol, quetiapine or healthy subjects
Discussion
EEG abnormalities seem to occur rarely in patients treated
with quetiapine comparable to the control group, but sig-
nificantly more often with haloperidol and olanzapine,
possibly due to different receptor profiles of these sub-
stances. Quetiapine might be considered as an treatment
option for neuropsychiatric patient, e.g. for patients with
the diagnosis of epilepsy or seizures with psychosis.
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